Cannabinoids for Dementia

MAURI BRUEGGEMAN | July 26, 2018

article image
One area of interest in the last year, as medical cannabis moves into the mainstream, is the use of cannabinoids for the treatment of dementia.  To be clear, many of the scientists or providers looking to cannabis or cannabinoid products are really looking at treating the symptoms associated with dementia, rather than the cause of dementia itself.  According to the literature, around half of patients with dementia experience behavioral and psychological symptoms (BPSD) which are distressing for everyone involved including the patient, caregivers, and family.  While it is widely accepted to use antipsychotics for these patients, many patients do not show significant improvement and suffer grave side effects as a result of that group of pharmaceuticals used.

Spotlight

PHASE II International

PHASE II is a full service communications agency serving life science companies worldwide. Our five divisions are structured to integrate, or work independently, as required.

OTHER ARTICLES

WALGREEN’S IN HOT WATER OVER PHONY PHARMACIST

Article | February 11, 2020

The drugstore chain agreed to pay $7.5 million in fines after an unlicensed pharmacist at several San Francisco Bay locations illegally filled more than 700,000 prescriptions over a ten-year period. According to California prosecutors, Kim Thien Le stole license numbers from other pharmacists to fill prescriptions for Fentanyl, morphine, and other painkillers. Le pleaded guilty to multiple felony impersonation counts. Walgreen’s agreed to the settlement to avoid being charged with consumer fraud in Alameda and Santa Anna Counties. Prosecutors alleged that Walgreen’s failed to verify Le’s license and did not conduct a thorough background check. The company insisted it has taken remedial measures.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | February 11, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Decentralized Clinical Trials: Imperative for Pharma Sector to fight COVID19

Article | February 11, 2020

These are unprecedented times. The world is mobbed by a contagion virus, putting people’s health at risk, threatening to destabilize economies. It has already put global healthcare systems under tremendous pressures, and managed to resist efforts to contain it. Even though coronaviruses are not new, this COVID-19 strain has created panic and forced us to be locked down in our homes sans any movement for weeks, if not months. Organizations are fighting an intense battle to keep their workforce safe, minimize risk, and ensure business continuity. For the Life Sciences industry, however, the challenge is even more significant. The whole world is looking at them to come up with a vaccine and a cure. But that is easier said than done. Bringing a new drug to market is an uphill battle and requires rigorous clinical trials. This process already has regulatory challenges. With the current lockdown situation, the Pharma community is grappled with the challenge of continuing some of the critical and time-sensitive in-flight trials so that their regulatory submission, registration, and market entry are not impacted. But all may not be lost. With the right technology solution, it is possible to turn the situation around rapidly.

Read More

Artificial intelligence in pharma: utilising a valuable resource

Article | February 11, 2020

The pharmaceutical industry is set to greatly benefit from the use of artificial intelligence (AI), due to its wide range of applications. Sydney Tierney discusses how machine learning can enhance marketing, manufacturing and drug trials. Artificial intelligence (AI) can be applied to nearly every aspect of the pharmaceutical and healthcare industry, to enhance data processing. Adopting the technology will reveal the astonishing potential of the healthcare sector, with success rates flying higher than ever before – especially in the research and development of crucial, life-changing drugs.

Read More

Spotlight

PHASE II International

PHASE II is a full service communications agency serving life science companies worldwide. Our five divisions are structured to integrate, or work independently, as required.

Events